In a report released yesterday, Gena Wang from Barclays reiterated a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target of $42.00. The company’s shares closed yesterday at $45.07.
Wang covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BioCryst, and Sarepta Therapeutics. According to TipRanks, Wang has an average return of 11.0% and a 47.52% success rate on recommended stocks.
In addition to Barclays, Beam Therapeutics also received a Hold from RBC Capital’s Luca Issi in a report issued yesterday. However, on the same day, William Blair maintained a Buy rating on Beam Therapeutics (NASDAQ: BEAM).
See the top stocks recommended by analysts >>
The company has a one-year high of $41.07 and a one-year low of $16.95. Currently, Beam Therapeutics has an average volume of 1.31M.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BEAM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Beam Therapeutics (BEAM) Company Description:
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Read More on BEAM:
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics, Inc. (BEAM) Q4 Earnings Cheat Sheet
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Beam Therapeutics upgraded to Overweight from Neutral at JPMorgan
